KemPharm Inc (KMPH) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Louis Casey

The stock of KemPharm Inc (NASDAQ:KMPH) is a huge mover today! The stock increased 5.97% or $0.2 on September 15, reaching $3.55. About 110,033 shares traded or 18.21% up from the average. KemPharm Inc (NASDAQ:KMPH) has declined 32.16% since September 17, 2016 and is downtrending. It has underperformed by 48.86% the S&P500.
The move comes after 6 months positive chart setup for the $52.03M company. It was reported on Sep, 17 by We have $3.87 PT which if reached, will make NASDAQ:KMPH worth $4.68M more.

Analysts await KemPharm Inc (NASDAQ:KMPH) to report earnings on November, 8. They expect $-0.69 EPS, up 25.00 % or $0.23 from last year’s $-0.92 per share. After $-0.44 actual EPS reported by KemPharm Inc for the previous quarter, Wall Street now forecasts 56.82 % negative EPS growth.

KemPharm Inc (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 14 analyst reports since August 14, 2015 according to SRatingsIntel. Roth Capital initiated it with “Buy” rating and $800 target in Wednesday, June 28 report. The stock of KemPharm Inc (NASDAQ:KMPH) has “Buy” rating given on Thursday, August 10 by Oppenheimer. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, August 10 report. The stock of KemPharm Inc (NASDAQ:KMPH) earned “Buy” rating by Canaccord Genuity on Thursday, September 17. The firm has “Buy” rating by Roth Capital given on Friday, August 11. RBC Capital Markets maintained it with “Outperform” rating and $14 target in Friday, May 6 report. The firm earned “Buy” rating on Tuesday, December 20 by Canaccord Genuity. Canaccord Genuity maintained KemPharm Inc (NASDAQ:KMPH) on Monday, September 11 with “Buy” rating. Oppenheimer maintained it with “Buy” rating and $1300 target in Wednesday, June 28 report. Oppenheimer maintained the shares of KMPH in report on Friday, September 18 with “Outperform” rating.

More notable recent KemPharm Inc (NASDAQ:KMPH) news were published by: which released: “KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results” on February 28, 2017, also with their article: “KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and …” published on March 27, 2017, published: “KemPharm Announces FDRR Process Completion and Resubmission of the Apadazâ„¢ NDA” on September 12, 2017. More interesting news about KemPharm Inc (NASDAQ:KMPH) were released by: and their article: “3.60” published on April 16, 2015 as well as‘s news article titled: “Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics …” with publication date: October 26, 2016.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The company has market cap of $52.03 million. The Firm is engaged in the discovery and development of prodrugs. It currently has negative earnings. The Firm uses its Ligand Activated Therapy platform technology to create prodrugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.